Bluejay Diagnostics, Inc. Announces Annual Meeting of Stockholders on May 14, 2024

Ticker: BJDX · Form: DEF 14A · Filed: 2024-04-15T00:00:00.000Z

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Stockholders, Voting, Bluejay Diagnostics

TL;DR

<b>Bluejay Diagnostics, Inc. invites stockholders to its Annual Meeting on May 14, 2024, urging prompt return of proxy cards.</b>

AI Summary

Bluejay Diagnostics, Inc. (BJDX) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Bluejay Diagnostics, Inc. will hold its Annual Meeting of Stockholders on May 14, 2024, at 1:00 p.m. local time. The meeting will take place at the company's corporate offices located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. Stockholders of record as of April 4, 2024, are eligible to receive proxy materials. Proxy materials are being distributed on or about April 22, 2024. Stockholders are urged to complete, date, and sign the proxy card and return it promptly.

Why It Matters

For investors and stakeholders tracking Bluejay Diagnostics, Inc., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the upcoming Annual Meeting of Stockholders, which is a standard procedural requirement for public companies to solicit votes. The information provided is crucial for shareholders to understand the matters to be voted on and to exercise their voting rights, either by proxy or in person.

Risk Assessment

Risk Level: low — Bluejay Diagnostics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Review the proxy statement for details on proposals to be voted on at the Annual Meeting to make an informed voting decision.

Key Numbers

May 14, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders.)
1:00 p.m. — Meeting Time (Local time the Annual Meeting will begin.)
April 4, 2024 — Record Date (Date to determine stockholders eligible to vote.)
April 22, 2024 — Distribution Date (Approximate date proxy materials are distributed.)

Key Players & Entities

Bluejay Diagnostics, Inc. (company) — Registrant and filer of the proxy statement.
May 14, 2024 (date) — Date of the Annual Meeting of Stockholders.
April 4, 2024 (date) — Record date for determining stockholders eligible to receive proxy materials.
April 22, 2024 (date) — Approximate date proxy materials are being distributed.
Neil Dey (person) — President and Chief Executive Officer of Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203, Acton, MA 01720 (location) — Corporate offices of Bluejay Diagnostics, Inc.

FAQ

When did Bluejay Diagnostics, Inc. file this DEF 14A?

Bluejay Diagnostics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 15, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Bluejay Diagnostics, Inc. (BJDX).

Where can I read the original DEF 14A filing from Bluejay Diagnostics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Bluejay Diagnostics, Inc..

What are the key takeaways from Bluejay Diagnostics, Inc.'s DEF 14A?

Bluejay Diagnostics, Inc. filed this DEF 14A on April 15, 2024. Key takeaways: Bluejay Diagnostics, Inc. will hold its Annual Meeting of Stockholders on May 14, 2024, at 1:00 p.m. local time.. The meeting will take place at the company's corporate offices located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.. Stockholders of record as of April 4, 2024, are eligible to receive proxy materials..

Is Bluejay Diagnostics, Inc. a risky investment based on this filing?

Based on this DEF 14A, Bluejay Diagnostics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.

What should investors do after reading Bluejay Diagnostics, Inc.'s DEF 14A?

Review the proxy statement for details on proposals to be voted on at the Annual Meeting to make an informed voting decision. The overall sentiment from this filing is neutral.

How does Bluejay Diagnostics, Inc. compare to its industry peers?

Bluejay Diagnostics, Inc. operates in the medical instruments and apparatus industry, focusing on diagnostic solutions.

Are there regulatory concerns for Bluejay Diagnostics, Inc.?

This filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.

Industry Context

Bluejay Diagnostics, Inc. operates in the medical instruments and apparatus industry, focusing on diagnostic solutions.

Regulatory Implications

This filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.

What Investors Should Do

Review the proxy statement for details on proposals and director nominations.
Complete and return the proxy card by the specified deadline to ensure your vote is counted.
Consider attending the Annual Meeting in person if feasible to directly participate in discussions and voting.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting of Stockholders, indicating a routine procedural update.

Filing Stats: 4,140 words · 17 min read · ~14 pages · Grade level 11.2 · Accepted 2024-04-15 16:46:24

Key Financial Figures

$21.80 — erlying options at an exercise price of $21.80 per share, (iv) 47 shares underl
$45.90 — rlying warrants at an exercise price of $45.90 per share, (v) 39 shares underly
$19.00 — rlying warrants at an exercise price of $19.00 per share, and (vi) 7,955 shares
$55.80 — erlying options at an exercise price of $55.80 per share, (iv) 125 shares under
$25 — erlying options at an exercise price of $25.20, and (v) 1,375 shares underly
$19.06 — erlying options at an exercise price of $19.06 per share, (iv) 125 shares under
$25.20 — erlying options at an exercise price of $25.20 per share, (v) 3,100 shares unde
$19.50 — rlying warrants at an exercise price of $19.50 per share and (vii) 1,375 shares
$3.24 — erlying options at an exercise price of $3.24 per share, (iv) 1,250 shares und
$70.00 — erlying options at an exercise price of $70.00 per share, (iii) 266 shares unde
$54.40 — erlying options at an exercise price of $54.40 per share, (ii) 125 shares under

Filing Documents

ea0202939-02.htm (DEF 14A) — 956KB
tproxy_001.jpg (GRAPHIC) — 1287KB
tproxy_002.jpg (GRAPHIC) — 1172KB
0001213900-24-033004.txt ( ) — 4345KB

From the Filing

DEF 14A 1 ea0202939-02.htm PROXY STATEMENT   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION __________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant   ☒ Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2)) ☒   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material Pursuant to §240.14a -12 Bluejay Diagnostics, Inc. (Name of Registrant as Specified In Its Charter) ____________________________________________________________ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒   No fee required.   Fee paid previously with preliminary materials.   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11     Table of Contents Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 (844) 327-7078 To the Stockholders of Bluejay Diagnostics, Inc.: You are cordially invited to attend the Annual Meeting of Stockholders of Bluejay Diagnostics, Inc. on May 14, 2024. The Annual Meeting will begin at 1:00 p.m. local time at the corporate offices of Bluejay Diagnostics, Inc., 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. Information regarding each of the matters to be voted on at the Annual Meeting is contained in the attached Proxy Statement and Notice of Annual Meeting of Stockholders. We urge you to read the proxy statement carefully. The proxy statement and proxy card are being mailed to all stockholders of record as of April 4, 2024. This proxy statement and proxy card are being distributed on or about April 22, 2024. Because it is important that your shares be voted at the Annual Meeting, we urge you to complete, date and sign the enclosed proxy card and return it as promptly as possible in the accompanying envelope, whether or not you plan to attend in person. Even after returning your proxy, if you are a stockholder of record and do attend the meeting and wish to vote your shares in person, you still may do so. We look forward to seeing you on May 14, 2024. Very truly yours, BLUEJAY DIAGNOSTICS, INC. By:   / s / Neil Dey         Neil Dey         President and Chief Executive Officer     Important Notice Regarding the Availability of Proxy Materials for the Annual Shareholder Meeting to be Held on May 14, 2024: Electronic Copies of the Proxy Statement and our 2023 Annual Report on Form 10 -K are available at https: // www.cstproxy.com / bluejaydx / 2024   Table of Contents Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 (844) 327 -7078 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held May 14, 2024 TO THE STOCKHOLDERS OF BLUEJAY DIAGNOSTICS, INC.: NOTICE IS HEREBY GIVEN that the 2024 Annual Meeting of Stockholders of Bluejay Diagnostics, Inc. (the “Company”) will be held at the corporate offices at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720, on May 14, 2024 at 1:00 p.m., Eastern Time, for the following purposes, as described in the accompanying Proxy Statement: Proposal 1.        To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2025 annual meeting of stockholders of the Company or until such person’s successor is qualified and elected. Proposal 2.        To approve and adopt an amendment to the Company’s amended and restated certificate of incorporation, as amended, to increase the number of authorized shares of the Company’s common stock. Proposal 3.        To approve and adopt an amendment to the Company’s amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock. Proposal 4.        To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2024. Proposal&#x00